Chief among a flurry of clinical advances in retina disease this year were the FDA approvals of complement inhibitors for GA and a higher-dose aflibercept for diabetic retinopathy. What comes next?
1. Avacincaptad pegol significantly slowed geographic atrophy over 12 months. 2. Exudative macular neovascularization was comparable among treatment groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Geographic atrophy is a severe form of age-related macular degeneration that can lead to irreversible vision loss. Currently, limited treatments exist. Avacincaptad pegol is a complement C5 inhibitor that
12-month GATHER2 results show monthly avacincaptad pegol 2 mg was well tolerated and showed significantly slower geographic atrophy growth than sham treatment.